Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 27, 2022, reports the outcome of a US Food and Drug Administration (FDA) Advisory Committee meeting regarding daprodustat, an oral treatment for anaemia of chronic kidney disease (CKD). The filing does not cover a financial reporting period but serves as a current report on a material regulatory development.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document focuses exclusively on clinical trial outcomes and regulatory status.
Material Changes and Regulatory Outcomes
- FDA Advisory Committee Vote (Dialysis Patients): The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 13 to 3 that the benefits of daprodustat outweigh the risks for adult dialysis patients with anaemia of CKD.
- FDA Advisory Committee Vote (Non-Dialysis Patients): The CRDAC voted 5 to 11 that the benefits do not outweigh the risks for adult non-dialysis patients with anaemia of CKD.
- Regulatory Timeline: The FDA accepted the New Drug Application (NDA) in April 2022 with a Prescription Drug User Fee Act date of February 1, 2023. The FDA is not bound by the committee's recommendation.
- Global Status: Daprodustat (Duvroq) is approved in Japan (June 2020) and is under regulatory review by the European Medicines Agency (EMA), with a decision expected in the first half of 2023.
Guidance, Outlook, and Management Commentary
Chris Corsico, Senior Vice President of Development at GSK, stated that the committee's recognition of daprodustat's potential for dialysis patients is a significant step, particularly given limited treatment options. Management expressed gratitude to the medical and patient communities for their insights and indicated a continued commitment to working with the FDA to complete the NDA review. The filing includes a standard cautionary statement regarding forward-looking statements, noting risks such as the impact of the COVID-19 pandemic and factors detailed in the 2021 Form 20-F.
Investor Verification Checklist
- Verify the final FDA approval decision for daprodustat in the US, noting the split advisory committee vote between dialysis and non-dialysis indications.
- Monitor the EMA regulatory decision timeline, currently anticipated in the first half of 2023.
- Review the commercial performance of Duvroq in Japan, where it is the market leader for HIF-PHI treatments.
- Assess the potential impact of the non-dialysis indication rejection on the total addressable market for daprodustat in the US.
- Confirm the February 1, 2023, PDUFA date for the US NDA review completion.